Executive Director, Government Affairs, Europe

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.

As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. This leader will be responsible for shaping and executing European government affairs priorities that support patient access, launch readiness, and long-term value for RevMed's innovative oncology portfolio. The role will focus on the evolving EU and country-level policy environment, including oncology access, pricing and reimbursement, HTA, innovation incentives, regulatory and legislative developments, and health system sustainability.

The Executive Director will be a key member of the Market Access leadership team to ensure that policy insights and external engagement are directly connected to access strategy, HTA planning, reimbursement, country launch sequencing, and stakeholder engagement. The role will partner closely with Corporate Communications / Corporate Affairs, Regulatory, Medical Affairs, Commercial, Legal, Compliance, Patient Advocacy, and global colleagues to ensure consistent and coordinated engagement across the company. This is a highly strategic, externally facing role for a senior leader who can establish the function, advise the business, represent RevMed credibly with policy stakeholders and industry associations, and translate the European policy landscape into practical business implications and opportunities.

Key Responsibilities

: Develop and lead the European government affairs strategy in alignment with Market Access, commercial readiness, global policy priorities, and RevMed's mission to serve patients with RAS-addicted cancers. Monitor, analyze, and communicate EU and country-level policy developments that may affect oncology innovation, HTA, pricing and reimbursement, patient access, clinical research, diagnostics, data, and launch execution. Provide strategic counsel to European and global leadership on policy risks, opportunities, and implications for launch planning, value strategy, access sequencing, and stakeholder engagement.

Establish and maintain strong working relationships with relevant policymakers, government officials, industry associations, professional organizations, patient organizations, and other external stakeholders, in close coordination with the Patient Advocacy function and consistent with company policies and applicable laws. Serve as the policy lead within the Market Access team, ensuring European policy perspectives are embedded into HTA readiness, payer engagement planning, value communication, reimbursement strategy, and country-level access plans. Work closely with Corporate Communications / Corporate Affairs to align policy positions, external messaging, reputation considerations, and issues management across European stakeholders.

Represent RevMed in relevant European and national trade associations, policy forums, and coalitions, and ensure internal teams are informed of key outputs and opportunities for engagement.

Requirements

, codes of